Zanidatamab in Previously-Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-up From the Phase 2b HERIZON-BTC-01 Study

Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase 2b HERIZON-BTC-01 trial (NCT04466891), after a median follow-up of 12.4 months, zanidatamab showed encouraging antitumor activity with rapid and durable responses and a manageable safety profile in patients with previously treated HER2+ BTC.

Related Content:

Rapid Readouts

Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)

Deep and Sustained Responses in Patients With CLL Treated With Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report From the Zanubrutinib Extension Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study